EKF Diagnostics Holdings PLC represents a strong commitment to providing innovative diagnostic solutions and improving patient outcomes. With a focus on precision medicine, the company aims to enhance healthcare delivery through advanced technologies. EKF Diagnostics values integrity, quality, and collaboration in its operations, fostering partnerships with healthcare professionals and researchers. By incorporating cutting-edge technologies and expertise, EKF Diagnostics strives to deliver accurate and reliable diagnostic tools for various medical conditions. The company's corporate philosophy emphasizes patient-centered care, technological advancements, and a drive for continuous improvement. EKF Diagnostics Holdings PLC constantly works towards advancing healthcare and empowering healthcare providers with reliable diagnostic solutions.

EKF Diagnostics Holdings PLC is primarily present in various countries and regions. These include the United Kingdom, Germany, Belgium, the United States, and Russia. With a global presence, EKF Diagnostics Holdings PLC has established a strong foothold in the healthcare industry. Its wide distribution network and strategic partnerships enable the company to provide innovative diagnostic solutions to healthcare professionals worldwide. EKF Diagnostics Holdings PLC's commitment to delivering accurate and reliable results makes it a trusted provider in the medical diagnostics market.

EKF Diagnostics Holdings PLC has achieved several significant milestones. The company successfully expanded its product portfolio by acquiring Stanbio Laboratory in 2011, which enabled them to provide a comprehensive range of diagnostic tests. In 2012, EKF Diagnostics entered into a collaboration agreement with Oragenics Inc. to develop and commercialize oral cancer diagnostic tests. Furthermore, they received US FDA clearance for their Quo-Test HbA1c analyzer in 2016, enhancing their presence in the diabetes diagnostics market. In 2018, EKF Diagnostics acquired DiaSpect Medical AB, a leading point-of-care hematology company. These milestones highlight the company's commitment to growth, innovation, and providing cutting-edge diagnostic solutions.

EKF Diagnostics Holdings PLC, a leading medical device and diagnostic services company, has a rich history and compelling background. Founded in 1990, EKF Diagnostics initially focused on developing enzymatic assays. Over the years, the company has grown exponentially, expanding its product portfolio and global presence. EKF Diagnostics is renowned for its cutting-edge technologies, such as point-of-care testing and molecular diagnostics, catering to various medical fields including diabetes, hematology, and oncology. The company's commitment to research, innovation, and high-quality products has earned it a strong reputation in the healthcare industry. EKF Diagnostics continues to thrive as a trusted provider of advanced diagnostic solutions, contributing to improved patient care worldwide.

The main competitors of EKF Diagnostics Holdings PLC in the market include companies such as Abbott Laboratories, Siemens Healthineers AG, and F. Hoffmann-La Roche Ltd. These companies are also prominent players in the medical diagnostics industry, offering a wide range of diagnostic products, including point-of-care testing solutions, clinical chemistry analyzers, and molecular diagnostics. However, EKF Diagnostics Holdings PLC distinguishes itself with its specialized focus on developing and manufacturing innovative diagnostic products for hematological, diabetes, and autoimmune conditions.

EKF Diagnostics Holdings PLC primarily operates in the medical diagnostics industry. With its robust portfolio of innovative diagnostic products and technologies, the company specializes in developing and manufacturing point-of-care analyzers, biomarker detection assays, and molecular diagnostics products. EKF Diagnostics Holdings PLC serves various sectors within the medical industry, such as clinical chemistry, hematology, diabetes, and infectious diseases. Leveraging its expertise, EKF Diagnostics aims to enhance patient outcomes and provide healthcare professionals with reliable tools for efficient diagnosis and monitoring.

The business model of EKF Diagnostics Holdings PLC revolves around the development, production, and distribution of innovative diagnostic tools and products. EKF Diagnostics specializes in point-of-care testing devices, molecular diagnostics, and central laboratory clinical chemistry. The company focuses on delivering cost-effective solutions that enable healthcare professionals to make accurate and timely diagnoses. EKF Diagnostics works closely with healthcare providers and laboratories worldwide to provide advanced diagnostic solutions that enhance patient care. By continuously investing in research and development, EKF Diagnostics aims to stay at the forefront of the diagnostic industry, addressing various medical needs efficiently and effectively.

EKF Diagnostics Holdings KGV ir 23,60.

EKF Diagnostics Holdings KUV ir 2,31.

AlleAktien kvalitātes vērtējums EKF Diagnostics Holdings ir 3/10.

gaidāmā EKF Diagnostics Holdings apgrozījums ir 55,80 milj. GBP.

gaidāmā EKF Diagnostics Holdings peļņa ir 5,46 milj. GBP.

EKF Diagnostics Holdings PLC is a company specializing in the development, manufacturing, and marketing of diagnostic and screening equipment for clinical laboratories. They focus on areas such as diabetes, hemoglobinopathies, hematology, infectious diseases, and cancer. Their business strategy includes selling products worldwide, capitalizing on the growing markets for point-of-care testing and mobile diagnostic devices. They achieve this through innovative technologies and partnerships with reputable research institutions and trade partners. The company's products include glucose meters, HbA1c analyzers, hemoglobinopathy analyzers, blood cell analyzers, and infection disease testing equipment. They also offer a range of products for cancer diagnostics. EKF Diagnostics operates globally with subsidiaries in Europe, Asia, and North America. They cater to various types of laboratories and offer custom solutions.

EKF Diagnostics Holdings izmaksā dividendes 0,01 GBP, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt EKF Diagnostics Holdings vai uzņēmums nedod dividendes.

EKF Diagnostics Holdings ISIN ir GB0031509804.

EKF Diagnostics Holdings WKN ir 622434.

EKF Diagnostics Holdings simbols ir EKF.L.

Pēdējo 12 mēnešu laikā EKF Diagnostics Holdings maksāja dividendes 0,01 GBP apmērā. Tas atbilst aptuveni 4,23 % dividendes ražībai. Nākamajos 12 mēnešos EKF Diagnostics Holdings plāno maksāt dividendes 0,01 GBP apmērā.

EKF Diagnostics Holdings pašreizējā dividendu rentabilitāte ir 4,23 %.

EKF Diagnostics Holdings maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos decembris, decembris, decembris, decembris.

EKF Diagnostics Holdings pēdējo 7 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0,01 GBP. Tas atbilst dividendes ražībai 3,85 %.

EKF Diagnostics Holdings tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu EKF Diagnostics Holdings apmērā 0,012 GBP, kas tika izmaksāta 1.12.2023., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 2.11.2023..

Pēdējās dividendes izmaksa notika 1.12.2023..

Gadā 2023, EKF Diagnostics Holdings izmaksāja 0,012 GBP dividendes.

EKF Diagnostics Holdings dividendes tiek izmaksātas GBP.